<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="113699">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01623076</url>
  </required_header>
  <id_info>
    <org_study_id>STU-022012-084</org_study_id>
    <nct_id>NCT01623076</nct_id>
  </id_info>
  <brief_title>A Longitudinal Study of Neuromyelitis Optica and Transverse Myelitis</brief_title>
  <official_title>A Longitudinal Study of Patients Diagnosed With or at Increased Risk for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to determine the biologic causes of inflammation in patients with
      Neuromyelitis Optica (NMO) and related conditions. While patients will be treated according
      to decisions with their treating physician, this study will collect data and samples from
      patients prospectively to gain a better understanding of the disease. We are seeking to
      understand why some patients respond to medications, while others do not. We also seek to
      understand what happens biologically, preceding relapses. Gathering these data and samples
      will allow researchers to identify new ways of diagnosing and treating these diseases. Data
      and samples will be shared with researchers around the world to support collaborative
      efforts to treat these conditions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Neuromyelitis Optica</condition>
  <condition>Neuromyelitis Optica Spectrum Disorder</condition>
  <condition>Transverse Myelitis</condition>
  <condition>Optic Neuritis</condition>
  <arm_group>
    <arm_group_label>Neuromyelitis Optica</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Neuromyelitis Optica Spectrum Disorder</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Transverse Myelitis and Optic Neuritis</arm_group_label>
    <description>Patients who have had one demyelinating event, not diagnosed with multiple sclerosis and whom are considered at risk for NMO or NMOSD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Patients will donate serum, plasma, DNA, RNA and white blood cells.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients previously diagnosed with Neuromyelitis Optica, Neuromyelitis Optica Spectrum
        Disorder, Transverse Myelitis and Optic Neuritis will be recruited to take part in a
        longitudinal study of their disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 6 years or greater

          -  Male or Female

          -  Patient or Parent (in the case of a minor) able to give informed consent

          -  For patients 10 to 17, patient able to assent

          -  Patient diagnosed with NMO, NMOSD, TM or ON

        Exclusion Criteria:

          -  Unable to maintain scheduled visits

          -  Patient has known HIV or hepatitis C infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dina Obrien, BA</last_name>
    <phone>214-645-7977</phone>
    <email>Dina.obrien@utsouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samuel Hughes, BS</last_name>
    <phone>214-645-0561</phone>
    <email>Samuel.Hughes@utsouthwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benjamin M Greenberg, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.myelitis.org/</url>
    <description>Transverse Myelitis Association</description>
  </link>
  <link>
    <url>http://www.guthyjacksonfoundation.org/</url>
    <description>Guthy Jackson Charitable Foundation for NMO</description>
  </link>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 5, 2013</lastchanged_date>
  <firstreceived_date>June 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Benjamin Greenberg</investigator_full_name>
    <investigator_title>Director, Neuromyelitis Optica and Transverse Myelitis Program</investigator_title>
  </responsible_party>
  <keyword>Neuromyelitis Optica</keyword>
  <keyword>Neuromyelitis Optica Spectrum Disorder</keyword>
  <keyword>Transverse Myelitis</keyword>
  <keyword>Optic Neuritis</keyword>
  <keyword>Biorepository</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Optic Neuritis</mesh_term>
    <mesh_term>Neuromyelitis Optica</mesh_term>
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Myelitis</mesh_term>
    <mesh_term>Myelitis, Transverse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
